Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitochondrial dysfunction and type 2 diabetes.

Rebecca Parish1, Kitt Falk Petersen

  • 1Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, PO Box 208020, New Haven, CT 06520-8020, USA.

Current Diabetes Reports
|June 3, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acquired ring chromosomes in hematological malignancies: A systematic evidence review for diagnostic advances, cytogenomic insights, and clinical significance by an International Consortium on Human Ring Chromosomes (ICHRC) working group.

Cancer genetics·2026
Same author

CIDEB and CGI-58 differentially regulate liver lipid-droplet cholesterol to modulate metabolic dysfunction-associated steatohepatitis severity.

Cell reports·2026
Same author

Distinct effects of ketogenic and non-ketogenic weight-loss diets on hepatic steatosis and mitochondrial metabolism in MASLD.

Journal of hepatology·2026
Same author

Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis.

bioRxiv : the preprint server for biology·2025
Same author

Glucagon promotes increased hepatic mitochondrial oxidation and pyruvate carboxylase flux in humans with fatty liver disease.

Cell metabolism·2024

Insulin resistance, a key factor in metabolic syndrome and type 2 diabetes, is linked to impaired glucose transport in muscle. Fatty acids inhibit this process by affecting key signaling proteins, revealing potential therapeutic targets.

Area of Science:

  • Metabolic disorders
  • Molecular biology
  • Biochemistry

Background:

  • Insulin resistance is central to metabolic syndrome and type 2 diabetes pathogenesis.
  • Mechanisms underlying insulin resistance are not fully understood.
  • Skeletal muscle glucose transport defects are implicated in insulin resistance.

Purpose of the Study:

  • To investigate the molecular mechanisms of insulin resistance.
  • To identify the role of fatty acids in impaired glucose transport.
  • To explore potential therapeutic targets for metabolic syndrome and type 2 diabetes.

Main Methods:

  • Magnetic resonance spectroscopy in human subjects.
  • Analysis of insulin signaling pathways, including tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1).

Related Experiment Videos

  • Assessment of IRS-1-associated phosphatidylinositol 3-kinase activity.

    • Main Results:

    • A defect in insulin-stimulated glucose transport in skeletal muscle is a primary abnormality in insulin resistance.
    • Fatty acids inhibit insulin-stimulated tyrosine phosphorylation of IRS-1 and IRS-1-associated phosphatidylinositol 3-kinase activity.
    • Increased intramyocellular and intrahepatic fatty acid metabolites contribute to insulin resistance.

    Conclusions:

    • Fatty acid accumulation disrupts insulin signaling, leading to impaired glucose transport.
    • Understanding these molecular defects offers novel therapeutic strategies for metabolic syndrome and type 2 diabetes.
    • Targeting fatty acid metabolism and insulin signaling pathways holds promise for treatment.